Product Name :
BMS-986020
Description:
BMS-986020 is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist. BMS-986020 inhibits bile acid and phospholipid transporters with IC50s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively. BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF).
CAS:
1257213-50-5
Molecular Weight:
482.53
Formula:
C29H26N2O5
Chemical Name:
1-4′-[3-methyl-4-([(1R)-1-phenylethoxy]carbonylamino)-1,2-oxazol-5-yl]-[1,1′-biphenyl]-4-ylcyclopropane-1-carboxylic acid
Smiles :
CC1=NOC(=C1NC(=O)O[C@H](C)C1C=CC=CC=1)C1C=CC(=CC=1)C1C=CC(=CC=1)C1(CC1)C(O)=O
InChiKey:
GQBRZBHEPUQRPL-LJQANCHMSA-N
InChi :
InChI=1S/C29H26N2O5/c1-18-25(30-28(34)35-19(2)20-6-4-3-5-7-20)26(36-31-18)23-10-8-21(9-11-23)22-12-14-24(15-13-22)29(16-17-29)27(32)33/h3-15,19H,16-17H2,1-2H3,(H,30,34)(H,32,33)/t19-/m1/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
BMS-986020 is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist. BMS-986020 inhibits bile acid and phospholipid transporters with IC50s of 4.8 µM, 6.2 µM, and 7.Gefapixant Formula 5 µM for BSEP, MRP4, and MDR3, respectively. BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF).|Product information|CAS Number: 1257213-50-5|Molecular Weight: 482.53|Formula: C29H26N2O5|Chemical Name: 1-4′-[3-methyl-4-([(1R)-1-phenylethoxy]carbonylamino)-1,2-oxazol-5-yl]-[1,1′-biphenyl]-4-ylcyclopropane-1-carboxylic acid|Smiles: CC1=NOC(=C1NC(=O)O[C@H](C)C1C=CC=CC=1)C1C=CC(=CC=1)C1C=CC(=CC=1)C1(CC1)C(O)=O|InChiKey: GQBRZBHEPUQRPL-LJQANCHMSA-N|InChi: InChI=1S/C29H26N2O5/c1-18-25(30-28(34)35-19(2)20-6-4-3-5-7-20)26(36-31-18)23-10-8-21(9-11-23)22-12-14-24(15-13-22)29(16-17-29)27(32)33/h3-15,19H,16-17H2,1-2H3,(H,30,34)(H,32,33)/t19-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 250 mg/mL (518.PSMA-11 Radionuclide-Drug Conjugates (RDCs) 10 mM; Need ultrasonic).PMID:32750813 |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|BMS-986020 (0.1-10 nM; pre-incubated) concentration-dependent displacement of [18F]BMT-083133 binding is observed in LPA1+ cells and lung sections. At 0.1 nM, the percent displacement in healthy mice, bleomycin mice, and IPF lungs is 18%, 24%, and 31%, respectively. At 10 nM, the percent displacement is 73%, 76%, and 64%, respectively. [18F]BMT-083133, a radioligand targeting LPA1 is developed as a translational research tool for assessment of lung LPA1 engagement of BMS-986020 using in vitro autoradiography (ARG).|Products are for research use only. Not for human use.|
